Compare
Liminatus Pharma, Inc. vs Zeo ScientifiX, Inc. vs BioCardia, Inc. vs Tevogen Inc.
| Latest fiscal year | Liminatus Pharma, Inc. LIMN | Zeo ScientifiX, Inc. ZEOX | BioCardia, Inc. BCDA | Tevogen Inc. TVGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-10-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $5.20M | $0 | n/a |
| Revenue growth (YoY) | n/a | +12.5% | -100.0% | n/a |
| Gross margin | n/a | 82.1% | n/a | n/a |
| Operating margin | n/a | -103.6% | n/a | n/a |
| Net margin | n/a | -106.2% | n/a | n/a |
| Net income | -$10.21M | -$5.52M | -$8.23M | -$26.28M |
| EPS (Diluted) | -$0.43 | -$0.86 | n/a | -$8.08 |
| Operating cash flow | -$9.96M | -$718.0K | -$7.44M | -$12.33M |
| Free cash flow | -$9.98M | -$741.0K | -$7.44M | -$12.39M |
| Cash & equivalents | n/a | n/a | $2.50M | $0 |
| Total assets | $512.8K | $1.53M | $3.41M | $4.38M |
| Total liabilities | $10.33M | $2.95M | $2.52M | $12.62M |
| Shareholders' equity | -$9.81M | -$1.42M | $895.0K | -$8.23M |
| Return on year-end equity | n/a | n/a | -919.3% | n/a |
| Shares outstanding | 27.06M | 6.75M | 10.76M | 4.02M |
Revenue, most recent five fiscal years
| Fiscal year | Liminatus Pharma, Inc. | Zeo ScientifiX, Inc. | BioCardia, Inc. | Tevogen Inc. |
|---|---|---|---|---|
| Latest | n/a | $5.20M Ended 2025-10-31 | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $4.62M Ended 2024-10-31 | $58.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $4.56M Ended 2023-10-31 | $477.0K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $6.49M Ended 2022-10-31 | $1.35M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $5.60M Ended 2021-10-31 | $1.01M Ended 2021-12-31 | n/a |